Cargando…

Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome

We aimed to evaluate the safety and immunogenicity of the BNT162b2 vaccine in young people with Down syndrome (DS), and to compare their humoral immune response with those of the healthy controls (HC). Individuals with DS and HC received the BNT162b2 vaccine. Longitudinal blood samples were collecte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Valentini, Diletta, Cotugno, Nicola, Scoppola, Vittorio, Di Camillo, Chiara, Colagrossi, Luna, Manno, Emma Concetta, Perno, Carlo Federico, Russo, Cristina, Palma, Paolo, Rossi, Paolo, Villani, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836979/ https://www.ncbi.nlm.nih.gov/pubmed/35160144 http://dx.doi.org/10.3390/jcm11030694

Ejemplares similares

Evaluation of Safety and Immunogenicity of BNT162B2 mRNA COVID-19 Vaccine in IBD Pediatric Population with Distinct Immune Suppressive Regimens
por: Cotugno, Nicola, et al.
Publicado: (2022)

Perinatally Human Immunodeficiency Virus–Infected Adolescents and Young Adults Demonstrate Distinct BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine Immunogenicity( )
por: Morrocchi, Elena, et al.
Publicado: (2022)

Humoral and Cellular Response Following Vaccination With the BNT162b2 mRNA COVID-19 Vaccine in Patients Affected by Primary Immunodeficiencies
por: Amodio, Donato, et al.
Publicado: (2021)

Induction of immune response after SARS-CoV-2 mRNA BNT162b2 vaccination in healthcare workers
por: Zaffina, Salvatore, et al.
Publicado: (2021)

Case Report: Successful Treatment With Monoclonal Antibodies in One APDS Patient With Prolonged SARS-CoV-2 Infection Not Responsive to Previous Lines of Treatment
por: Rivalta, Beatrice, et al.
Publicado: (2022)

Sleep and behavioral problems in preschool-age children with Down syndrome
por: Fucà, Elisa, et al.
Publicado: (2022)

Highly Specific Memory B Cells Generation after the 2nd Dose of BNT162b2 Vaccine Compensate for the Decline of Serum Antibodies and Absence of Mucosal IgA
por: Piano Mortari, Eva, et al.
Publicado: (2021)

Immunogenicity and safety of BNT162b2 COVID‐19 vaccine in a chronic lymphocytic leukaemia patient
por: Agrati, Chiara, et al.
Publicado: (2021)

Association between Reactogenicity and Immunogenicity after Vaccination with BNT162b2
por: Bauernfeind, Stilla, et al.
Publicado: (2021)

Effects of Pidotimod on recurrent respiratory infections in children with Down syndrome: a retrospective Italian study
por: Valentini, Diletta, et al.
Publicado: (2020)

Immunogenicity of a BNT162b2 vaccine booster in health-care workers
por: Saiag, Esther, et al.
Publicado: (2021)

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
por: Frenck, Robert W., et al.
Publicado: (2021)

Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
por: Zurac, Sabina, et al.
Publicado: (2022)

Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults
por: Priddy, Frances H., et al.
Publicado: (2022)

Sleep and behavioral problems in Down syndrome: differences between school age and adolescence
por: Fucà, Elisa, et al.
Publicado: (2023)

Early antiretroviral treatment (eART) limits viral diversity over time in a long-term HIV viral suppressed perinatally infected child
por: Palma, Paolo, et al.
Publicado: (2016)

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
por: Payne, Rebecca P., et al.
Publicado: (2021)

Humoral and Cellular Immunogenicity of 3 Doses of BNT162b2 in Children With Kidney Diseases
por: Leung, Daniel, et al.
Publicado: (2023)

Fatal varicella pneumonia in an unvaccinated child with Down Syndrome: a case report
por: Valentini, Diletta, et al.
Publicado: (2016)

Artificial Intelligence Applied to in vitro Gene Expression Testing (IVIGET) to Predict Trivalent Inactivated Influenza Vaccine Immunogenicity in HIV Infected Children
por: Cotugno, Nicola, et al.
Publicado: (2020)

Medium-to-Long-Term Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine: A Retrospective Cohort Study
por: Bianchi, Francesco Paolo, et al.
Publicado: (2022)

Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience
por: Peled, Yael, et al.
Publicado: (2022)

Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine in Patients with Cardiovascular Disease
por: Naruse, Hiroyuki, et al.
Publicado: (2021)

Reduced immunogenicity of the mRNA vaccine BNT162b2 in patients with idiopathic pulmonary fibrosis
por: Karampitsakos, Theodoros, et al.
Publicado: (2022)

Immunogenicity of the COVID-19 BNT162b2 vaccine in adolescents and young adults with cystic fibrosis
por: Michos, Athanasios, et al.
Publicado: (2022)

Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID‐19 vaccines in Hong Kong
por: Mok, Chris Ka Pun, et al.
Publicado: (2021)

Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults
por: Murdoch, Louise, et al.
Publicado: (2023)

The mRNA vaccine BNT162b2 demonstrates impaired T(H)1 immunogenicity in human elders in vitro and aged mice in vivo
por: Brook, Byron, et al.
Publicado: (2022)

Evaluation of Immunogenicity to Three Doses of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Lung Transplant Patients
por: Guardiani, Mariasilvia, et al.
Publicado: (2022)

Performance evaluation of a new on-demand molecular test for the rapid identification of severe acute respiratory syndrome coronavirus 2 in pediatric and adult patients
por: Colagrossi, Luna, et al.
Publicado: (2022)

Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers
por: Tober-Lau, Pinkus, et al.
Publicado: (2021)

Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer
por: Ligumsky, Hagai, et al.
Publicado: (2022)

Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines
por: Zhang, Ruiqi, et al.
Publicado: (2022)

Safety and immunogenicity of the COVID-19 vaccine BNT162b2 in patients undergoing chemotherapy for solid cancer
por: Funakoshi, Yohei, et al.
Publicado: (2022)

Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru
por: Vargas-Herrera, Natalia, et al.
Publicado: (2022)

Down Syndrome in FPIES: An Overwhelming and Unexpected Prevalence
por: Pecora, Valentina, et al.
Publicado: (2022)

Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon
por: Moghnieh, Rima, et al.
Publicado: (2021)

OMIC Technologies and Vaccine Development: From the Identification of Vulnerable Individuals to the Formulation of Invulnerable Vaccines
por: Cotugno, Nicola, et al.
Publicado: (2019)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Vernal keratoconjunctivitis in Down syndrome: a case report
por: Artesani, Maria Cristina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vbaqt90rn54cmgh7qcujifcn9l